Japan to Use iPS Cells in Clinical Trial for Cancer Patients
Newsfrom JapanSociety Lifestyle Science
Tokyo, Jan. 10 (Jiji Press)--A Japanese team is preparing to start a clinical trial to inject immune cells made from induced pluripotent stem, or iPS, cells into head and neck cancer patients, it was learned Thursday.
The team of Riken and Chiba University researchers will file for state approval of the trial as early as autumn and start it as soon as the approval is given, informed sources said.
The clinical trial will be the first one in Japan that utilizes iPS cells to test cancer treatment.
Key members of the team include Haruhiko Koseki, executive of the Riken Center for Integrative Medical Sciences, and Chiba University Prof. Yoshitaka Okamoto.
The trial is expected to be conducted on three patients with recurrent cancers that cannot be sufficiently treated by surgery.
[Copyright The Jiji Press, Ltd.]